GB1390772A - Oral narcotic composition - Google Patents

Oral narcotic composition

Info

Publication number
GB1390772A
GB1390772A GB1131972A GB1131972A GB1390772A GB 1390772 A GB1390772 A GB 1390772A GB 1131972 A GB1131972 A GB 1131972A GB 1131972 A GB1131972 A GB 1131972A GB 1390772 A GB1390772 A GB 1390772A
Authority
GB
United Kingdom
Prior art keywords
narcotic
salts
composition
orally
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1131972A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDO LAB
ENDO LABORATORIES Inc
Original Assignee
ENDO LAB
ENDO LABORATORIES INC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14140771A priority Critical
Application filed by ENDO LAB, ENDO LABORATORIES INC filed Critical ENDO LAB
Publication of GB1390772A publication Critical patent/GB1390772A/en
Application status is Expired legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine

Abstract

1390772 Narcotic compositions ENDO LABORATORIES INC 10 March 1972 [7 May 1971] 11319/72 Heading A5B Pharmaceutical compositions comprise: (a) a compound, having substantial narcotic activity both orally and by injection, selected from oxycodone, hydrocodone, codeine, propoxyphene and pentazocine, and salts thereof and, (b) a narcotic antagonist which is substantially less active orally than by injection selected from: (i) naloxone and its pharmaceutically acceptable salts, (ii) N-cyclopropylmethyl-7, 8-dihydro-14-hydroxynormophinone and its salts and, (iii) 21-cyclopropyl-7#-(1- hydroxy-1-methylethyl)-6, 14-endo-ethano-tetrahydrooripavine and its salts, the weight ratio of (a) to (b) being within certain ranges according to the individual compounds used so that substance (b) does not block the narcotic effect of (a) when the composition is administered orally, but does prevent an acute euphoriant effect by (a) when the composition is injected. Other active substances may also be present, e.g. aspirin, phenacetin, caffeine, antihistamines and antispasmodics.
GB1131972A 1971-05-07 1972-03-10 Oral narcotic composition Expired GB1390772A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14140771A true 1971-05-07 1971-05-07

Publications (1)

Publication Number Publication Date
GB1390772A true GB1390772A (en) 1975-04-16

Family

ID=22495561

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1131972A Expired GB1390772A (en) 1971-05-07 1972-03-10 Oral narcotic composition

Country Status (3)

Country Link
DE (1) DE2222039A1 (en)
FR (1) FR2137560B1 (en)
GB (1) GB1390772A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0900582A1 (en) * 1997-08-21 1999-03-10 Johnson Matthey Public Limited Company Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
EP1299104A1 (en) * 2000-02-08 2003-04-09 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
WO2003084520A2 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP1810678A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
AU2402392A (en) * 1991-08-06 1993-03-02 Byk Gulden Lomberg Chemische Fabrik Gmbh New anti-diarrheic agents
FR2681922B1 (en) * 1991-09-30 1993-11-26 Bendix Europe Services Technique friction member provided with a wear indicator and brake device has anywhere a disc such a body.
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1414451B1 (en) 2001-08-06 2009-05-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981751A (en) * 1997-08-12 1999-11-09 Johnson Matthey Public Limited Company Method for removal of residual organic solvents and use thereof in manufacturing pharmaceuticals
EP0900582A1 (en) * 1997-08-21 1999-03-10 Johnson Matthey Public Limited Company Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8357399B2 (en) 2000-02-08 2013-01-22 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
EP1299104A4 (en) * 2000-02-08 2004-04-21 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
AP1665A (en) * 2000-02-08 2006-09-22 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9801828B2 (en) 2000-02-08 2017-10-31 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
EP1299104A1 (en) * 2000-02-08 2003-04-09 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
CZ299991B6 (en) * 2000-02-08 2009-01-14 Euro-Celtique S.A. Medicamentous dosage form
CN100563656C (en) 2000-02-08 2009-12-02 欧罗赛铁克股份有限公司 Tamper-resistant oral opioid agonist
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7682632B2 (en) 2000-02-08 2010-03-23 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7718192B2 (en) * 2000-02-08 2010-05-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842309B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842311B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8236351B2 (en) 2000-02-08 2012-08-07 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8586088B2 (en) 2000-02-08 2013-11-19 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
WO2003007802A3 (en) * 2001-07-18 2003-11-27 Christopher D Breder Pharmaceutical combinations of oxycodone and naloxone
US8758825B2 (en) 2001-08-06 2014-06-24 Purdue Pharma L.P. Sequestered antagonist formulations
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
WO2003084520A3 (en) * 2002-04-05 2004-03-11 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
JP4755810B2 (en) * 2002-04-05 2011-08-24 ユーロ−セルティーク エス.エイ. Pharmaceutical formulations containing oxycodone and naloxone
EP2425825B1 (en) 2002-04-05 2016-11-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
JP2010180233A (en) * 2002-04-05 2010-08-19 Euro-Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
CN1646102B (en) 2002-04-05 2012-08-15 欧洲凯尔蒂克公司 Pharmaceutical preparation containing oxycodone and naloxone
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
AU2003224040B2 (en) * 2002-04-05 2006-06-22 Mundipharma Pty Limited Pharmaceutical preparation containing oxycodone and naloxone
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
WO2003084520A2 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
EP1810678A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
WO2007082935A1 (en) * 2006-01-19 2007-07-26 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
EA014539B1 (en) * 2006-01-19 2010-12-30 Фенукс Аг Use of a combination of morphine and at least one opiate antagonists for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
US9370512B2 (en) 2006-08-30 2016-06-21 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9763931B2 (en) 2006-08-30 2017-09-19 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9861628B2 (en) 2006-08-30 2018-01-09 Rhodes Pharmaceuticals L.P. Buprenorphine-wafer for drug substitution therapy
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Also Published As

Publication number Publication date
DE2222039A1 (en) 1972-11-23
FR2137560A1 (en) 1972-12-29
FR2137560B1 (en) 1975-10-31

Similar Documents

Publication Publication Date Title
Blane et al. Blockade of bradykinin‐induced nociception in the rat as a test for analgesic drugs with particular reference to morphine antagonists
US4834965A (en) Controlled release pharmaceutical composition
US4237140A (en) Analgesic mixture of nalbuphine and acetaminophen
US3773955A (en) Analgetic compositions
US4309405A (en) Sustained release pharmaceutical compositions
AT278806B (en) A process for the preparation of novel Azaspiroalkandionverbindungen as well as their pharmaceutically acceptable acid addition salts
GB1222708A (en) Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation
AU528190B2 (en) Device for oral administration of drugs to ruminant animals
US4474813A (en) Pharmaceutical preparations comprising flutamide
Möller et al. Comparative studies on intramuscular and oral effective doses of some anticholinergic drugs
US4309404A (en) Sustained release pharmaceutical compositions
DE3067536D1 (en) Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof
BG60834B2 (en) Pharmaceutical compositions based on phosphonoformic acid and their application
GB885081A (en) Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride
SK283081B6 (en) Solid peroral application form with regulated releasing
AT119393T (en) Use of an opiate antagonist medicament to be administered transdermally for the production of a well as a device for transdermal administration.
SK282895B6 (en) Peptides having growth hormone releasing activity, pharmaceutical composition containing it and their preparation process
JPS601128A (en) Long-acting cefaclor preparation
US4366159A (en) Nalbuphine-narcotic analgesic composition and method of producing analgesia
JPS62258316A (en) Novel pharmaceutical preparation of acid-unstable substance for oral administration
SE7614576A (en) Orally administrable pharmaceutical composition
GB1083193A (en) Guanidine derivatives and process for their manufacture
HK90687A (en) Dosage form for coadministering drug and percutaneous absorption enhancer
KR950007853A (en) Cancer treatment
Armstrong et al. Initial clinical experience with vinglycinate sulfate, a molecular modification of vinblastine

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees
49R Reference inserted (sect. 9/1949)
SP Amendment (slips) printed